Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

DSIP

Emideltide, DSIP nonapeptide, Delta sleep-inducing peptide

Quick Stats
Studies 458
Trials 82
Score 2
1989 pubmed 2 citations

Involvement of spinal noradrenergic system in the mechanism of an antinociceptive effect of delta-sleep-inducing peptide (DSIP).

Nakamura. A A; Sugao. T T; Yamaue. K K; Kobatake. M M; Shiomi. H H

Key Findings

  • DSIP injected into the brain reduces pain responses in mice (tail‑pinch and hot‑plate tests).
  • Depleting monoamines with reserpine removes DSIP’s antinociceptive effect.
  • Blocking spinal alpha‑adrenergic receptors (with phentolamine or yohimbine) also blocks DSIP’s pain‑relief, while a serotonin blocker does not.
  • The results point to the spinal noradrenergic pathway as the main route for DSIP’s analgesic action.

Practical Outcomes

  • DSIP appears to relieve pain by activating spinal noradrenaline pathways, suggesting a possible mechanism for its analgesic effects. However, the study used brain‑ventricular injections in mice, which isn’t a feasible method for self‑administration, and no human dosing data are provided. For biohackers, the finding is interesting but not yet actionable for real‑world protocols; more research is needed before considering DSIP for pain management or performance enhancement.

Summary

In mice, a peptide called delta‑sleep‑inducing peptide (DSIP) can lessen pain, but it only works when the brain’s descending noradrenaline (noradrenergic) system is intact. If the body’s monoamine stores are depleted or if spinal alpha‑adrenergic receptors are blocked, DSIP’s pain‑relief disappears. Serotonin doesn’t seem to play a role.

Abstract

We studied whether the antinociceptive effect produced by intracerebroventricular injection of delta-sleep-inducing peptide (DSIP) to mice involved the monoaminergic pathways that descended from brainstem to spinal cord (the descending inhibitory systems). In the tail-pinch test, the antinociceptive effect of DSIP was significantly reduced by the pretreatment with reserpine (3 mg/kg i.p.) which depleted endogenous monoamines. Moreover, the intrathecal injections of monoamine antagonists were performed to evaluate the roles of the spinal noradrenergic and/or serotonergic systems in the production of the DSIP antinociception. In both tail-pinch and hot plate tests, the antinociceptive effect of DSIP was significantly antagonized by the previous intrathecal administration of phentolamine (an alpha-adrenergic blocker) or yohimbine (an alpha 2-adrenergic blocker), but was unaffected by the pretreatment with methysergide (a serotonin antagonist). These results demonstrate that the activation of the descending inhibitory systems, mainly spinal noradrenergic systems, is involved in the elicitation of DSIP antinociception.

Study Information

Provider

pubmed

Year

1989

Date

1989-02-20T00:00:00.000Z

DOI

10.1016/0006-8993(89)91569-2

Citations

2

References

22